Bristol Myers Squibb’s Post

The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase as a result of a steady increase in prevalence, the chronic nature of IBD (and thus the need for long-term, often expensive treatments), the use of more intensive disease monitoring strategies, and the effects of IBD on economic productivity. The aim of The Lancet Gastroenterology & Hepatology Commission was to examine the current costs of IBD care and the drivers involved in increasing economic burden, and to explore means to deliver affordable, equitable care for patients with IBD in the future. https://bit.ly/42XPk8B | #InflammatoryBowelDisease #PrecisionDosing #PrecisionMedicine #IBDCare

Important progress has been issued in 2023 in the field of inflammatory bowel disease #naturereviewsgastroenterologyandhepatology Kotze, P.G., Vermeire, S. Upgrading therapeutic ambitions and treatment outcomes. Nat Rev Gastroenterol Hepatol (2023). https://lnkd.in/dgrs44Np

These panelists should have included some experts in #healthcommunications in their discussions related to updating fatty liver disease nomenclature. Now, #NAFLD will become metabolic dysfunction-associated steatotic liver disease (#MASLD). Although the new terminology may be more medically precise, it is less clear for #patients. I predict "fatty liver" will continue to be used clinically despite this newly adopted nomenclature simply because very few patients will understand the new terms. If you're developing any patient-/public-facing materials on this condition, please use words patients will understand. #medicalwriting #medcomms #liverhealth #medicine #communications

In the 📕#RedJournal: Practical Considerations to Optimize Care for Patients With Alcohol-Associated Liver Disease in General Gastroenterology Practice Perumalswami, et al. 👉 bit.ly/3wcqLdA

This JAMA Clinical Guidelines Synopsis summarizes the American Association of Clinical Endocrinology’s 2022 clinical practice guideline for diagnosis and management of nonalcoholic fatty liver disease. https://ja.ma/40uaj35

Excited to share that our meta-analysis abstract titled "Prevalence and Risk of Migraine in Inflammatory Bowel Disease" was presented at the American College of Gastroenterology Annual Scientific Meet 2023. It's now published in the American Journal of Gastroenterology. Our study found no significant association between the risk of migraine and IBD. Title: S919 Prevalence and Risk of Migraine in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis DOI: 10.14309/01.ajg.0000953316.34565.23

Alcohol-associated liver disease (#ALD) is a major global health concern, leading to high rates of liver-related morbidity and mortality. A new Consensus Statement by Mack Mitchell, Laura Nagy & colleagues highlights the urgent need for clinical trials to explore effective treatments that integrate approaches for both ALD and alcohol use disorder (#AUD). The guidelines, published in Nature Reviews Gastroenterology & Hepatology, delve into the complexities of treating ALD alongside AUD, emphasizing the importance of combining methodologies from both fields to enhance the quality and effectiveness of clinical trials. After an extensive literature search and discussion of expert opinion, 28 recommendations for clinical trials of alcohol use and ALD were developed, with recommendations related to definitions of alcohol use, minimum data sets, statistical considerations and more. READ HERE: https://lnkd.in/eBVa_p3M An accompanying News & Views by Juliana Serrazine & Helena Cortez-Pinto puts these new recommendations into context and discuss how the new guidelines offer a structured framework for conducting research in this field, which should hopefully facilitate development of novel therapies. READ HERE: https://rdcu.be/dKNhq #alcoholusedisorder #alcoholrelatedliverdisease #liverdisease #alcoholpolicy #alcoholuse #alcoholassociatedliverdisease #steatoticliverdisease #metALD

Acute Hepatitis could advance to affect the liver and lead to life-threatening complications, including liver cirrhosis and failure. Timely intervention could prevent the worsening of the condition. On #WorldHepatitisDay, Dr. Kaushal Madan, Principal Director & Head, Clinical Hepatology, Max Smart Hospital, Saket, explains the differences between Chronic and Acute Hepatitis by pointing out their respective symptoms and causes. #Hepatitis #LiverHealth #MaxHealthcare

Promoting equity in inflammatory bowel disease: a 🌍global approach to care 🫶 S Sebastian and important comment in new edition of The Lancet Gastroenterology & Hepatology 🫵 read, remember & comapre with yours & yours #IBDpatients reality Where You were, You will be or maybe You are FOUR 🏛️PILLARS collaborate advocate research educate 🗞 https://lnkd.in/dQFUw7id #ECCO UEG - United European Gastroenterology American College of Gastroenterology British Society of Gastroenterology (BSG) World Gastroenterology Organisation (WGO) European Federation of Crohn's and Ulcerative Colitis Associations CrohnsColitisLifestyle Crohn's & Colitis Foundation Crohn's & Colitis UK #IBD #InflammatoryBowelDisease #UC #UlcerativeColitis #WJZG #WrzodziejąceZapalenieJelitaGrubego #CD #CrohnsDisease #ChL_C #ChorobaLeśniowskiego_Crohna

In case you missed it... Explore the challenges of diagnosing IgG4-related gastrointestinal disease and stay up to date with current and emerging treatment options with top experts, Professor Matthias Löhr and Dr Shounak Majumder Watch now: https://lnkd.in/e6DwNm-f This content is for healthcare professionals only. This activity is funded by an independent medical education grant from Horizon Therapeutics. This activity is jointly provided by USF Health and touchIME. #IgG4 #GastrointestinalDisease #Gastrointesinal #Gastro #Pancreas #DigestiveDisorder #RareDisease #Rheumatology #Hepatology